Stay Tuned!

Subscribe to our newsletter to get our newest articles instantly!

Business

Sanofi Consumer Healthcare Korea appoints former Pierre-Fabre Dermo Cosmetique Korea GM as new CEO

[ad_1]


Sanofi Consumer Healthcare (CHC) Korea said Thursday it appointed Cheong Kyung-hui, former general manager (GM) at Pierre Fabre Dermo Cosmetique Korea GM, as its new CEO.


Sanofi Consumer Healthcare Korea has appointed Cheong Kyung-hui as the company's new CEO.
Sanofi Consumer Healthcare Korea has appointed Cheong Kyung-hui as the company’s new CEO.


Cheong has built her career in the marketing and digital fields at various global companies for the past 26 years, and is evaluated as a person with the expertise to lead consumer business through excellent organizational skills and driving force, the company said


From November 2020 to May 2021, Cheong served as the GM of Pierre Fabre Dermo Cosmetique Korea, leading in-house cultural innovation to improve group-wide performance and organizational efficiency. She also served as brand general manager at ELCA Korea, leading the successful sales growth of major brands such as Aveda, Clinique, and Lab series, and conducted brand growth strategies by serving as the head of brand and marketing at leading companies such as Unilever and SK Gas.


“It is a great honor to serve as the CEO of Sanofi’s CHC division, which contributes to creating a healthy society through scientific new products,” Cheong said. “Based on past experiences, I will do my best to bring out the potential and balanced growth of the CHC division.”

[ad_2]

Source link

Avatar

Trish Basangar

About Author

Leave a comment

Your email address will not be published. Required fields are marked *

You may also like

Business

W Energy Software Hires New CEO

[ad_1] TULSA, Okla.–(BUSINESS WIRE)–W Energy Software, a leading provider of cloud-based accounting and Enterprise Resource Planning (ERP) software for enterprise
Business

EDWARDS LIFESCIENCES ANNOUNCES CEO SUCCESSION PLAN

[ad_1] IRVINE, Calif., Dec. 8, 2022 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW) today announced that following regular succession planning